 The purpose of open-label study is to evaluate the efficacy and safety of AO-128 Voglibose 0.6 mgday in patients with impaired glucose tolerance IGT who had been non-responsive to diet therapy and exercise therapy, and follow up the progress after the end of treatment in patients who was assessed as normoglycemic. 